Proportion of Patients Requiring Temporary (>1 Day) or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks of First Dose of AZD2171 12 week treatment period [clinicaltrials_resource:a62f8a7d755a8da876693615387f17eb]
Total actual dose received during the first 12 weeks prior to progression divided by the planned dose (planned dose: initial allocated dose multiplied by the number of days on study during the first 12 weeks prior to progression)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Proportion of Patients Requiring Temporary (>1 Day) or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks of First Dose of AZD2171 12 week treatment period [clinicaltrials_resource:a62f8a7d755a8da876693615387f17eb]
Total actual dose received during the first 12 weeks prior to progression divided by the planned dose (planned dose: initial allocated dose multiplied by the number of days on study during the first 12 weeks prior to progression)
Bio2RDF identifier
a62f8a7d755a8da876693615387f17eb
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a62f8a7d755a8da876693615387f17eb
measure [clinicaltrials_vocabulary:measure]
Proportion of Patients Requiri ...... Weeks of First Dose of AZD2171
time frame [clinicaltrials_vocabulary:time-frame]
12 week treatment period
description
Total actual dose received dur ...... 12 weeks prior to progression)
identifier
clinicaltrials_resource:a62f8a7d755a8da876693615387f17eb
title
Proportion of Patients Requiri ...... D2171 12 week treatment period
@en
type
label
Proportion of Patients Requiri ...... f8a7d755a8da876693615387f17eb]
@en